TAIWAN LIPOSOME/S (NASDAQ:TLC) Raised to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of TAIWAN LIPOSOME/S (NASDAQ:TLC) from a hold rating to a buy rating in a research report report published on Tuesday morning, Zacks.com reports. They currently have $6.00 target price on the stock.

According to Zacks, “Taiwan Liposome Company Ltd. is a specialty pharmaceutical company. It focuses on development and commercialization of novel nanomedicines designed to target unmet medical need in pain management, ophthalmology and oncology. The company’s product pipeline consists of TLC599, TLC590, TLC399 and TLC178 which are in clinical stage. Taiwan Liposome Company Ltd. is headquartered in Taipei City, Taiwan. “

TLC has been the subject of a number of other reports. Cantor Fitzgerald reiterated a buy rating and set a $11.00 price target on shares of TAIWAN LIPOSOME/S in a report on Monday, March 18th. HC Wainwright reiterated a buy rating on shares of TAIWAN LIPOSOME/S in a report on Thursday, April 18th. Five equities research analysts have rated the stock with a buy rating, The stock has an average rating of Buy and an average price target of $9.50.

TLC opened at $5.50 on Tuesday. TAIWAN LIPOSOME/S has a twelve month low of $5.02 and a twelve month high of $11.00. The company has a market capitalization of $180.01 million and a P/E ratio of -11.70. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.45 and a quick ratio of 3.45.

TAIWAN LIPOSOME/S (NASDAQ:TLC) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.19. TAIWAN LIPOSOME/S had a negative return on equity of 150.37% and a negative net margin of 414.31%. The company had revenue of $5.11 million during the quarter, compared to analyst estimates of $3.00 million. Equities analysts expect that TAIWAN LIPOSOME/S will post -0.82 earnings per share for the current year.

Hedge funds have recently modified their holdings of the company. Karst Peak Capital Ltd acquired a new position in shares of TAIWAN LIPOSOME/S during the fourth quarter worth approximately $3,129,000. Millennium Management LLC acquired a new position in shares of TAIWAN LIPOSOME/S during the fourth quarter worth approximately $602,000. Finally, Morgan Stanley lifted its holdings in shares of TAIWAN LIPOSOME/S by 257,350.0% during the first quarter. Morgan Stanley now owns 257,450 shares of the company’s stock worth $1,502,000 after buying an additional 257,350 shares during the last quarter. Institutional investors own 2.94% of the company’s stock.


Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.

Featured Article: How is the discount rate different from the Federal Funds rate?

Get a free copy of the Zacks research report on TAIWAN LIPOSOME/S (TLC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with MarketBeat.com's FREE daily email newsletter.